TNSN07040A1 - Proteines de fusion de rage et methodes d'utilisation - Google Patents

Proteines de fusion de rage et methodes d'utilisation

Info

Publication number
TNSN07040A1
TNSN07040A1 TNP2007000040A TNSN07040A TNSN07040A1 TN SN07040 A1 TNSN07040 A1 TN SN07040A1 TN P2007000040 A TNP2007000040 A TN P2007000040A TN SN07040 A TNSN07040 A TN SN07040A TN SN07040 A1 TNSN07040 A1 TN SN07040A1
Authority
TN
Tunisia
Prior art keywords
rage
fusion proteins
domain
methods
rage fusion
Prior art date
Application number
TNP2007000040A
Other languages
English (en)
Inventor
Adnan M M Mjalli
David M Stern
Ye E Tian
Jeffrey C Webster
Robert Rothlein
Ann Marie Schmidt
Shi Du Yan
Original Assignee
Transtech Pharma Inc
The Trustees Of Colombia Univ In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35427536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN07040(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transtech Pharma Inc, The Trustees Of Colombia Univ In The City Of New York filed Critical Transtech Pharma Inc
Publication of TNSN07040A1 publication Critical patent/TNSN07040A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Il est décrit des protéines de fusion de RAGE, comprenant des séquences de polypeptides RAGE liées à un second polypeptide non du type RAGE. La protéine de fusion de RAGE peut utiliser un domaine de polypeptide RAGE comprenant un site de liaison de ligand de RAGE et un segment de liaison inter-domaines lié directement à un domaine CH2 d'immunoglobuline. De telles protéines de fusion peuvent présenter une liaison spécifique à forte affinité élevée à des ligands de RAGE. Il est décrit également l'utilisation de protéines de fusion de RAGE comme agents thérapeutiques pour des pathologies à médiation par RAGE.
TNP2007000040A 2004-08-03 2007-02-02 Proteines de fusion de rage et methodes d'utilisation TNSN07040A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59836204P 2004-08-03 2004-08-03
PCT/US2005/027694 WO2006017643A1 (fr) 2004-08-03 2005-08-03 Protéines de fusion récepteurs de type rage et procédés d'utilisation de celles-ci

Publications (1)

Publication Number Publication Date
TNSN07040A1 true TNSN07040A1 (fr) 2008-06-02

Family

ID=35427536

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000040A TNSN07040A1 (fr) 2004-08-03 2007-02-02 Proteines de fusion de rage et methodes d'utilisation

Country Status (23)

Country Link
US (2) US20060078562A1 (fr)
EP (1) EP1776459A1 (fr)
JP (1) JP2008508882A (fr)
KR (1) KR20070057818A (fr)
CN (1) CN101010430A (fr)
AP (1) AP2007003893A0 (fr)
AU (2) AU2005271449A1 (fr)
BR (1) BRPI0514013A (fr)
CA (1) CA2575830A1 (fr)
CR (2) CR8897A (fr)
EA (1) EA012586B1 (fr)
EC (1) ECSP077297A (fr)
GE (1) GEP20105111B (fr)
IL (1) IL180555A0 (fr)
MA (1) MA28781B1 (fr)
MX (1) MX2007001556A (fr)
NO (1) NO20070062L (fr)
NZ (1) NZ552842A (fr)
SG (1) SG161242A1 (fr)
TN (1) TNSN07040A1 (fr)
UA (1) UA92154C2 (fr)
WO (1) WO2006017643A1 (fr)
ZA (1) ZA200700641B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
ATE378418T1 (de) * 1998-10-06 2007-11-15 Univ Columbia Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen
AU2002213192A1 (en) * 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
EP1575513A4 (fr) * 2002-08-16 2007-04-04 Wyeth Corp Compositions et methodes de traitement de troubles associes au recepteur rage
WO2004100890A2 (fr) 2003-05-09 2004-11-25 The Trustees Of Columbia University In The City Of New York Procedes lies a la fonction rage g82s et compositions destinees au traitement de troubles inflammatoires
US7470521B2 (en) * 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
WO2006017647A1 (fr) * 2004-08-03 2006-02-16 Transtech Pharma, Inc. Protéines hybrides rage et leurs procédés d'utilisation
US20060078562A1 (en) * 2004-08-03 2006-04-13 Mjalli Adnan M RAGE fusion proteins and methods of use
AU2005289594B2 (en) * 2004-09-27 2012-02-02 Centocor, Inc. Srage mimetibody, compositions, methods and uses
US20090220484A1 (en) * 2005-03-17 2009-09-03 Ann Marie Schmidt Rage/Diaphanous Interaction and Related Compositions and Methods
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
CN101331384B (zh) * 2005-12-23 2011-11-09 G科德系统有限公司 定位图形
BRPI0707640A2 (pt) * 2006-02-09 2011-05-10 Transtech Pharma Inc proteÍnas de fusço do rage e mÉtodos de uso
EA017291B1 (ru) * 2006-05-05 2012-11-30 Транстек Фарма, Инк. Белки слияния на основе rage, их композиции и способы их применения
EP2423220B1 (fr) 2007-01-30 2015-04-29 Epivax, Inc. Épitopes de lymphocytes t régulateurs, compositions et utilisations de ceux-ci
WO2008100470A2 (fr) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Protéines de fusion de l'immunoglobuline et procédés de fabrication
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
MX2009013194A (es) * 2007-06-14 2010-03-30 Galactica Pharmaceuticals Inc Proteinas de fusion del receptor para productos finales de glicacion avanzada.
NL2001555C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001553C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001552C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001551C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001557C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001556C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001558C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001554C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
EP2421892A1 (fr) 2009-04-20 2012-02-29 Pfizer Inc. Contrôle de la glycosylation de protéines, compositions et méthodes associées
WO2013103688A1 (fr) * 2012-01-03 2013-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs humains solubles pour produits finaux de glycation avancée (srage), procédé de préparation de srage humain et traitement et procédés utilisant un srage
CN103376328A (zh) * 2013-07-18 2013-10-30 上海交通大学医学院附属瑞金医院 血清sRAGE水平的检测试剂在筛选改善胰岛素β细胞功能的糖尿病治疗药物中的应用
KR101645654B1 (ko) * 2014-05-02 2016-08-05 서울대학교산학협력단 Rage로부터 유래된 폴리펩티드 및 이를 유효성분으로 포함하는 뇌혈관질환의 예방 또는 치료용 약학적 조성물
CA3112637A1 (fr) 2018-09-14 2020-03-19 BioAge Labs, Inc. Proteines de fusion rage presentant une stabilite et une affinite de liaison aux ligands ameliorees et leurs utilisations
JP7479039B2 (ja) 2019-02-21 2024-05-08 国立研究開発法人農業・食品産業技術総合研究機構 糖尿病診断技術
JP7477141B2 (ja) * 2019-02-21 2024-05-01 国立研究開発法人農業・食品産業技術総合研究機構 肝疾患診断技術

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) * 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
NO315930B1 (no) * 1995-01-18 2003-11-17 Picower Inst For Medical Res T Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser
JP4067562B2 (ja) * 1995-01-18 2008-03-26 アルテオン インコーポレイテッド 進行性グリコシル化最終生成物の生成を阻止し、反転するためのチアゾリウム化合物の使用
US5656261A (en) * 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
CA2217572A1 (fr) * 1995-04-05 1996-10-10 The Picower Institute For Medical Research Agents se liant a des produits finals de glycosylation evolues et leurs methodes d'utilisation
US5747035A (en) * 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
ZA988461B (en) * 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
US6380165B1 (en) * 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US6753150B2 (en) * 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
ATE378418T1 (de) * 1998-10-06 2007-11-15 Univ Columbia Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6605642B2 (en) * 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
AU6766800A (en) * 1999-08-13 2001-03-13 Trustees Of Columbia University In The City Of New York, The Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof
US20050170382A1 (en) * 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
EP1252305A2 (fr) * 1999-12-08 2002-10-30 Genset Adnc humains pleine longueur codant pour des proteines potentiellement secretees
WO2001079842A2 (fr) * 2000-04-14 2001-10-25 Niadyne Corporation Procede d'identification de regulateurs de la formation de produits finaux de glycation a avancement proteique (« age » proteique
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US6825164B1 (en) * 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
US6563015B1 (en) * 2000-08-14 2003-05-13 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof
IL155174A0 (en) * 2000-10-02 2003-10-31 Reddy Us Therapeutics Inc Methods and compositions for the treatment of inflammatory diseases
AU2002213192A1 (en) * 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US20050244849A1 (en) * 2000-12-15 2005-11-03 Genetics Institute, Llc Screening assays for rheumatoid arthritis
BR0116606A (pt) * 2000-12-29 2006-05-09 Reddy Us Therapeutics Inc métodos e composições para detecção de compostos que modulam as respostas inflamatórias
US7189830B2 (en) * 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
JP2004523565A (ja) * 2001-03-05 2004-08-05 トランス　テック　ファーマ，インコーポレイテッド 治療因子としてのベンゾイミダゾール誘導体
CA2440042C (fr) * 2001-03-05 2011-09-27 Transtech Pharma, Inc. Derives de carboxamide utilises comme agents therapeutiques
JP3837494B2 (ja) * 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
US6861888B2 (en) * 2002-01-16 2005-03-01 Agilent Technologies, Inc. High-sensitivity differential data latch system
ATE529110T1 (de) * 2002-03-05 2011-11-15 Transtech Pharma Inc Mono- und bicyclische azolderivate die die interaktion von liganden mit rage hemmen
EP1575513A4 (fr) * 2002-08-16 2007-04-04 Wyeth Corp Compositions et methodes de traitement de troubles associes au recepteur rage
WO2004100890A2 (fr) * 2003-05-09 2004-11-25 The Trustees Of Columbia University In The City Of New York Procedes lies a la fonction rage g82s et compositions destinees au traitement de troubles inflammatoires
WO2005021710A2 (fr) * 2003-06-02 2005-03-10 University Of Miami Molecules chimeres et procedes d'utilisation correspondants
US6969545B2 (en) * 2003-07-28 2005-11-29 Deere & Company Hydrogen storage container
US20070014791A1 (en) * 2003-09-05 2007-01-18 Schmidt Ann M Rage-related methods and copositions for treating glomerular injury
WO2005042032A1 (fr) * 2003-10-31 2005-05-12 The Trustees Of Columbia University In The City Of New York Procedes pour traiter la sclerose en plaques
US20080260717A1 (en) * 2003-10-31 2008-10-23 Trustees Of Columbia University In The City Of New York Methods for Reducing Seizure-Induced Neuronal Damage
US7470521B2 (en) * 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
WO2006017647A1 (fr) * 2004-08-03 2006-02-16 Transtech Pharma, Inc. Protéines hybrides rage et leurs procédés d'utilisation
US20060078562A1 (en) * 2004-08-03 2006-04-13 Mjalli Adnan M RAGE fusion proteins and methods of use
AU2005289594B2 (en) * 2004-09-27 2012-02-02 Centocor, Inc. Srage mimetibody, compositions, methods and uses
US20090220484A1 (en) * 2005-03-17 2009-09-03 Ann Marie Schmidt Rage/Diaphanous Interaction and Related Compositions and Methods
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
BRPI0707640A2 (pt) * 2006-02-09 2011-05-10 Transtech Pharma Inc proteÍnas de fusço do rage e mÉtodos de uso
EA017291B1 (ru) * 2006-05-05 2012-11-30 Транстек Фарма, Инк. Белки слияния на основе rage, их композиции и способы их применения
WO2008100470A2 (fr) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Protéines de fusion de l'immunoglobuline et procédés de fabrication
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
US9491184B2 (en) * 2008-04-04 2016-11-08 Samsung Electronics Co., Ltd. Method and apparatus for managing tokens for digital rights management

Also Published As

Publication number Publication date
US20060078562A1 (en) 2006-04-13
US20090060925A1 (en) 2009-03-05
AP2007003893A0 (en) 2007-02-28
WO2006017643A1 (fr) 2006-02-16
UA92154C2 (ru) 2010-10-11
MA28781B1 (fr) 2007-08-01
ECSP077297A (es) 2007-05-30
EA012586B1 (ru) 2009-10-30
EA200700402A1 (ru) 2007-08-31
AU2010201531A1 (en) 2010-05-06
AU2005271449A1 (en) 2006-02-16
CR20110557A (es) 2011-12-05
GEP20105111B (en) 2010-11-10
EP1776459A1 (fr) 2007-04-25
BRPI0514013A (pt) 2008-05-27
CR8897A (es) 2007-06-29
NO20070062L (no) 2007-01-31
CA2575830A1 (fr) 2006-02-16
JP2008508882A (ja) 2008-03-27
ZA200700641B (en) 2008-10-29
CN101010430A (zh) 2007-08-01
MX2007001556A (es) 2008-03-05
SG161242A1 (en) 2010-05-27
IL180555A0 (en) 2007-06-03
NZ552842A (en) 2010-05-28
KR20070057818A (ko) 2007-06-07

Similar Documents

Publication Publication Date Title
TNSN07040A1 (fr) Proteines de fusion de rage et methodes d'utilisation
TNSN07037A1 (fr) Proteines de fusion de rage et methodes d'utilisation
Strickland et al. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor.
SG171670A1 (en) Rage fusion proteins, formulations, and methods of use thereof
WO2007094926A3 (fr) Protéines hybrides rage et leurs procédés d'utilisation
WO2006002161A3 (fr) Modulateurs de recepteurs odorants
EP2371390A3 (fr) Antagonistes et leurs procédés d'utilisation
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
DE69637570D1 (de) Varianten des wachstumsfaktors der vaskulären endothelzellen, ihre verwendung sowie methoden für ihre herstellung
ATE394485T1 (de) Neue g protein-gekoppelte rezeptor proteine, dnas davon und liganden für diese
KR930703008A (ko) 복합된 특이성 융합 단백질
ATE504599T1 (de) Zur aktivierung von rezeptoren fähige fusionspolypeptide
Zhou et al. Purification and molecular identification of the human hyaluronan receptor for endocytosis
PL378566A1 (pl) Ligandy dla białek wiążących TGF-beta i ich zastosowania
ATE499384T1 (de) Multimere fc-rezeptor-polypeptide
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
Lubbers et al. Carbamylation reduces the capacity of IgG for hexamerization and complement activation
DE60319135D1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
Wu et al. Receptors specific for Amadori-modified glycated albumin on murine endothelial cells
DE69909312D1 (de) Methoden zur identifizierung von "hot-spot" resten bindender proteine und kleine verbindungen die an diese binden
ATE359263T1 (de) Substitutierte aminosaeuren als erythropoietin- mimetica
Medgyesi et al. Functional mapping of the FcγRII binding site on human IgG1 by synthetic peptides
WO2006047049A3 (fr) Fragments polypeptidiques nogo-a, polypeptides du recepteur-1 nogo de variants, et leurs utilisations
Fretz et al. Targeting a hydrophobic patch on the surface of the Grb2-SH2 domain leads to high-affinity phosphotyrosine-containing peptide ligands
Shin et al. Evidence for Glial Sodium-Calcium Exchanger 1 Association with Caveolin-1 and 2